Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
The study fell short of a clean sweep, with Pfizer finding no effect on survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Nick Paul Taylor
Apr 28, 2025 7:25am
Bioxodes halts phase 2 stroke trial after interim review success
Apr 24, 2025 9:32am
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Apr 24, 2025 4:46am
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
Apr 23, 2025 7:25am
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
Apr 17, 2025 6:45am
Mural's IL-2 flop triggers 90% staff reduction
Apr 15, 2025 9:33am
